562. Tocilizumab for the Treatment of Severe COVID-19: A Retrospective, Multi-Center, Case-Matched Series

BACKGROUND: At the time of this writing, there is no FDA approved medication for the treatment of COVID-19. One medication currently under investigation for COVID-19 treatment is tocilizumab, an interleukin-6 (IL-6) inhibitor. It has been shown there are increased levels of cytokines including IL-6...

Descripción completa

Detalles Bibliográficos
Autores principales: Norman, Sarah, Jones, Sara, Reeves, David, Cheatham, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776610/
http://dx.doi.org/10.1093/ofid/ofaa439.756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776610/
http://dx.doi.org/10.1093/ofid/ofaa439.756

Ejemplares similares